Gara Jalqabaatti › Leukemia Myeloidii Hamaa › Massachusetts › Boston
Qorannoo klinikaalii Leukemia Myeloidii Hamaa Boston, MA keessatti
Qorannoo 44 Leukemia Myeloidii Hamaa f Boston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Namoota walitti qabaa jiraSadarkaa 3
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Tufts Medical Center, Boston
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Namoota walitti qabaa jiraSadarkaa 2
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana-Farber Cancer Center, Boston
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Namoota walitti qabaa jiraSadarkaa 3
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Namoota walitti qabaa jiraSadarkaa 2
- Dana-Farber Cancer Institute, Boston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
CIML NK Cells With Venetoclax for AML
Namoota walitti qabaa jiraSadarkaa 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana-Farber Cancer Institute, Boston
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Namoota walitti qabaa jiraSadarkaa 3
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 1
- Beth Israel Deaconess Medical Center, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Namoota walitti qabaa jiraSadarkaa 1Hojjettoota fayyaa simatamoo
- Brigham and Women's Hospital, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Namoota walitti qabaa jiraQorannoo ilaalaa
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Ivosidenib as Post-HSCT Maintenance for AML
Namoota walitti qabaa jiraSadarkaa 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 1
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Namoota walitti qabaa jiraQorannoo ilaalaa
- Dana-Farber Cancer Institute, Boston
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Namoota walitti qabaa jiraSadarkaa 1
- Beth Israel Deaconess Medical Center, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Namoota walitti qabaa jiraSadarkaa 2/3
- Dana-Farber Cancer Institute, Boston
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Namoota walitti qabaa jiraSadarkaa 2
- Dana-Farber Cancer Institute, Boston
Revumenib in Combination With 7+3 + Midostaurin in AML
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
Ziftomenib Maintenance Post Allo-HCT
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Namoota walitti qabaa jiraSadarkaa 2
- Dana-Farber Cancer Institute, Boston
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
- DFCI/BWH Brigham and Women's Hospital, Boston
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Namoota walitti qabaa jiraSadarkaa 1
- DFCI, Boston
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Namoota walitti qabaa jiraSadarkaa 1/2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Novel Digital Application for Patients With Acute Leukemia
Namoota walitti qabaa jira
- Massachusetts General Hospital (MGH), Boston
IS-free Treg HaploHCT
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Study of REM-422 in Patients With AML or Higher Risk MDS
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
Qorannoo Leukemia Myeloidii Hamaa magaalota biroo keessatti
- Houston, TXQorannoo 85
- New York City, NYQorannoo 51
- Baldwin Park, CAQorannoo 40
- Seattle, WAQorannoo 40
- Columbus, OHQorannoo 35
- Philadelphia, PAQorannoo 34
- Durham, NCQorannoo 33
- Atlanta, GAQorannoo 30
- Tampa, FLQorannoo 29
- Chicago, ILQorannoo 26
- Portland, ORQorannoo 25
- Miami, FLQorannoo 24
Qorannoo biroo Boston keessatti
- Saree OljooQorannoo 111
- Kansara Qara'a Non-Small CellQorannoo 90
- Saree (Gosoota Hunda)Qorannoo 86
- Kansarii ColorectalQorannoo 63
- Kansara MetastatikiiQorannoo 63
- Dhibee QaraQorannoo 62
- Kansarii OvariiQorannoo 61
- Kansarii ProstateQorannoo 59
- DepreshiniiQorannoo 52
- Kansa EndometiriyaaliiQorannoo 50
- Cufama OnneeQorannoo 44
- Kansarii PancreasQorannoo 43
Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.